Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Auraptene (7-geranyloxycoumarin) is a naturally occurring monoterpene coumarin ether, primarily isolated from citrus fruits (e.g., oranges, grapefruits, lemons) and some edible plants of the *Ferula* genus. It is structurally derived from coumarin, with a geranyl group attached at position 7. Auraptene exhibits a broad range of biological activities, including potent anti-inflammatory, anticancer, anti-bacterial, antioxidant, neuroprotective, and hepatoprotective properties. Its anticancer effects have been demonstrated in vitro (e.g., inhibition of multiple cancer cell lines, induction of apoptosis, downregulation of BCL2, upregulation of p53) and in vivo, with proposed mechanisms involving modulation of leukocyte activation, induction of phase II detoxifying enzymes, and inhibition of enzymes such as β-secretase (BACE1). It shows promising therapeutic value for chronic illnesses such as hypertension, nonalcoholic fatty liver disease, cystic fibrosis, and potentially neurodegenerative diseases like Alzheimer's disease. Auraptene is under active investigation as a chemopreventive agent, often in dietary and nutraceutical research[1][5][7][3][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on auraptene.